This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages before signing in

CHARM Alternative trial

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

The CHARM-Alternative trial recruited 2028 ACE inhibitor-intolerant patients with heart failure due to left ventricular dysfunction. The patients were randomised to either candesartan or placebo.

Treatment with candesartan (an angiotensin receptor antagonist) gave clear reductions in mortality and hospital admissions.

Reference:

Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, Ostergren J, Pfeffer MA, Swedberg K; CHARM Investigators and Committees. (2003). Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 362(9386):772-6.

 

 

Related pages

Create an account to add page annotations

Create a free account

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.